Navigation Links
Clinical Data Reported on Vidaza in Hematologic Malignancies and,Advanced Solid Tumors

sed as labeled. Pharmacokinetic data for the two agents in combination is similar to either drug alone. The responses are summarized as: five complete responses (CR), five complete responses with incomplete peripheral count recovery (CR-i) and one partial response (PR). Significant HDAC activity inhibition was seen in most patients.

Enrollment is ongoing and expected to be complete by year end. Subsequent studies are planned including potentially larger randomized trials in either or both patient populations (MDS and AML).

(Back to top)

About Hodgkin's Lymphoma

Hodgkin's lymphoma (HL) is a cancer of the lymphatic system that begins in the lymph nodes and progresses to other organs, including the lungs, liver, bone and bone marrow. It is characterized by the presence of Reed-Sternberg cells. Currently, there is no known cause of the disease, but the Epstein-Barr virus, HIV and familial history are known risk factors. The disease is slightly more prevalent in men than women, and the median age is 38. Approximately 151,000 cases of HL exist in the U.S., and an estimated 8,000 new cases of HL will be diagnosed this year in the U.S.

About Myelodysplastic Syndromes (MDS) and Acute Myelogenous Leukemia (AML)

Myelodysplastic syndromes are a serious and life-threatening group of diseases in which the bone marrow does not function normally, resulting in the production of malformed or immature blood cells. The disease begins when a defect occurs in the genetic material (chromosomes) of one of the stem cells in the bone marrow. That stem cell in turn produces cells that carry the defect. The defective cells eventually predominate in the bone marrow and overwhelm healthy blood cells. These defective cells are less able to produce functioning blood cells, which results in low blood cell counts (cytopenias) in the bloodstream.

Without enough healthy blood cells - red, white and platelets - people with MDS are at risk for a variety o
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29

Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
4. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
Post Your Comments:
(Date:12/16/2009)... Dec. 16 BioSpecifics Technologies Corp. (Nasdaq: ... in class collagenase-based products, today announced top-line efficacy ... trial of XIAFLEX(TM) for the treatment of Peyronie,s ... of inelastic collagen on the shaft of the ... sexual intercourse difficult or impossible in advanced cases. ...
(Date:12/16/2009)... -- MAQUET Cardiovascular LLC, a leading provider ... has signed a three-year single source provider ... contracting company, for MAQUET,s market-leading VASOVIEW Endoscopic ... assist healthcare providers in obtaining veins for ... small incisions. This allows for faster healing, ...
(Date:12/16/2009)... -- The Boards of Silence Therapeutics plc (AIM: ... the merger of their businesses to form a ... interference). The enlarged company, to be called ... and delivery technologies, a broad internal and partnered ... property. ,, The Directors believe the merger ...
Breaking Medicine Technology:BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronie's Disease 2BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronie's Disease 3BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronie's Disease 4MAQUET Cardiovascular Awarded Three-Year Single Source Contract From Novation for VASOVIEW Endoscopic Vessel Harvesting Devices 2MAQUET Cardiovascular Awarded Three-Year Single Source Contract From Novation for VASOVIEW Endoscopic Vessel Harvesting Devices 3MAQUET Cardiovascular Awarded Three-Year Single Source Contract From Novation for VASOVIEW Endoscopic Vessel Harvesting Devices 4Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company 2Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company 3Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company 4Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company 5Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company 6CuraGen Updates CR011 vcMMAE Data at ASCO 4512 1CuraGen Updates CR011 vcMMAE Data at ASCO 4512 2CuraGen Updates CR011 vcMMAE Data at ASCO 4512 3CuraGen Updates CR011 vcMMAE Data at ASCO 4512 4CuraGen Updates CR011 vcMMAE Data at ASCO 4512 5CuraGen Updates CR011 vcMMAE Data at ASCO 4512 6CuraGen Updates CR011 vcMMAE Data at ASCO 4512 7Abbott 26 BioGenex Extend the Technology Co development and Distribution Agreement for Marketing the Xmatrx 28R 29 Advanced Staining Platform for the 12406 1Abbott 26 BioGenex Extend the Technology Co development and Distribution Agreement for Marketing the Xmatrx 28R 29 Advanced Staining Platform for the 12406 2The Killing of George Tiller 3A Video 26quot 3BThine Eyes 26quot 3B Shows True Face of Pro life Movement in the Face of 26apos 3BTerrorist 26apos 3 47577 1The Killing of George Tiller 3A Video 26quot 3BThine Eyes 26quot 3B Shows True Face of Pro life Movement in the Face of 26apos 3BTerrorist 26apos 3 47577 2
... alfa-2b) dosed every two weeks met the primary ... peginterferon alfa-2a dosed weekly in patients with genotype ... 900-mcg Albuferon had comparable rates of serious and/or ... of global marketing applications planned in fall 2009 ...
... 6 The American Medical Association (AMA) Foundation announced today the 28 ... the program provides $2,500 grants to medical students, physician residents and fellows ... award winners are conducting research in the following four categories: , ... Cardiovascular/pulmonary diseases , HIV/AIDS , ...
Other Medicine Technology:Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 2Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 3Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 4Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 5Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 6Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 7Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 8Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 9Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 10AMA Foundation Announces Seed Grant Research Recipients 2AMA Foundation Announces Seed Grant Research Recipients 3
(Date:12/16/2009)... Dec. 16 Shoppers like knowing if ... or Argentina. But grocers have found it burdensome ... (COOL) laws requiring them to provide the information ... at easyCOOLnow.com for easily making grocery ... include provisions that require retailers of unprocessed fruits, ...
(Date:12/16/2009)... MassMutual,s Retirement Services Division has announced plans to ... Q2 2010. The new platform will include a ... materials in a variety of themes. Plan sponsors ... menu of creative options to support the theme ... new RetireSmart participant engagement platform will be phased ...
(Date:12/16/2009)... School of Medicine,s (BUSM) Pulmonary Center has received ... Heart, Lung, and Blood Institute to derive stem ... disease. , Darrell Kotton, MD, associate professor ... PhD, assistant professor of medicine, are the principal ... and Mostoslavsky lead a multicenter investigative team of ...
(Date:12/16/2009)... agency, is honored to announce that Chris Wepfer and Jackie ... Year in Healthcare Traveler magazine’s 2009 Recruiters of the Year ... received such honors and the first for Jackie. , ... ... Solutions, a national healthcare staffing agency, is honored to announce ...
(Date:12/16/2009)... Medizone International, Inc. (OTC Bulletin Board: MZEI) ... the Board of Medizone New Zealand Ltd., a ... a 50% interest, agreed on December 14, 2009 ... Medizone International all global marketing rights of the ... G. Marshall said, "Time has eroded the relevance ...
Breaking Medicine News(10 mins):Health News:New Website Helps Grocers Comply With COOL Laws 2Health News:MassMutual to Launch New RetireSmart(SM) Participant Engagement Platform 2Health News:MassMutual to Launch New RetireSmart(SM) Participant Engagement Platform 3Health News:MassMutual to Launch New RetireSmart(SM) Participant Engagement Platform 4Health News:MassMutual to Launch New RetireSmart(SM) Participant Engagement Platform 5Health News:Boston University School of Medicine's pulmonary center receives $1.4 million grant 2Health News:Medical Solutions is Proud to Announce Chris Wepfer and Jackie Kirby as the Company's Recruiter of the Year Recipients 2Health News:Medical Solutions is Proud to Announce Chris Wepfer and Jackie Kirby as the Company's Recruiter of the Year Recipients 3Health News:Medizone International, Inc. Approves Repurchase of Global Marketing Rights 2
... Calif., May 12 Medical Care Corporation (MCC), ... technology, announced today that physicians now have a ... Screen, which enables them to accurately separate normal ... of memory loss associated with an underlying medical ...
... Call to Action demonstrates commitment to combating a leading ... and WaterAid America released two new reports today that ... are not responding to clear evidence on child mortality ... Diarrheal disease, a leading killer of children under age ...
... the skin , , TUESDAY, May 12 (HealthDay News) -- Any ... eased chronic lower back pain in a group of adult ... Cherkin, lead author of a report published in the May ... "Acupuncture is an effective treatment for chronic back pain. People ...
... Week 2009 -CAMBRIDGE, Mass. and NEW YORK, May 12, ... (NYSE: FRX ) today announced they will ... studies for linaclotide, a first-in-class investigational compound for the ... chronic constipation (CC), during the 2009 Digestive Disease Week ...
... 12 Last month The National Alliance of Advocates for ... patients seeking treatment for painkiller or heroin addiction compared to ... track for an astounding 200% gain. Dr. Michael Stein, author ... Oprah Magazine and The New York Times , tells ...
... MOUNTAIN VIEW, Calif., May 12 Based on ... market, Frost & Sullivan recognizes Sypris Test & ... & Sullivan Customer Service Leadership Award. This ... constant innovations, and strategic partnerships that have given ...
Other Medicine News:Health News:Medical Care Corporation Enables Early Detection of Memory Loss Due to Alzheimer's Disease 2Health News:Two New Reports Highlight Stalled Progress Against Diarrheal Disease: Nearly 1.6 Million Children Die Each Year From These Preventable and Treatable Diseases 2Health News:Two New Reports Highlight Stalled Progress Against Diarrheal Disease: Nearly 1.6 Million Children Die Each Year From These Preventable and Treatable Diseases 3Health News:Two New Reports Highlight Stalled Progress Against Diarrheal Disease: Nearly 1.6 Million Children Die Each Year From These Preventable and Treatable Diseases 4Health News:Acupuncture, Real or Fake, Eases Back Pain 2Health News:Acupuncture, Real or Fake, Eases Back Pain 3Health News:Ironwood and Forest to Present Additional Phase 2b Data for Novel Gastrointestinal Agent Linaclotide 2Health News:Ironwood and Forest to Present Additional Phase 2b Data for Novel Gastrointestinal Agent Linaclotide 3Health News:Ironwood and Forest to Present Additional Phase 2b Data for Novel Gastrointestinal Agent Linaclotide 4Health News:Economy Impacts People Seeking Treatment for Addiction - 80% Increase Over Last Year 2Health News:Economy Impacts People Seeking Treatment for Addiction - 80% Increase Over Last Year 3Health News:Frost & Sullivan Acknowledges Sypris for High-Quality Calibration Solutions 2Health News:Frost & Sullivan Acknowledges Sypris for High-Quality Calibration Solutions 3Health News:Frost & Sullivan Acknowledges Sypris for High-Quality Calibration Solutions 4
QualCraft™ Euro Lite has a molded nylon frame that fits most faces. Universal keyhole nose bridge fits narrow to average noses. Available with or without lead vinyl-lined side shields....
QualCraft™ Radiation-Reducing Eyewear is 50% lighter than other protective eyewear. Manufactured for the ultimate combination of comfort, function, and protection....
Clip-On Glasses clip onto regular eyewear frames. Plano (nonprescription) only. Will not fit over high-plus or high-minus presciptions, or over glasses with thick frames. Black wire frames. Wt. 63 g....
Portable shields for your safety and convenience....
Medicine Products: